NHS
Oxford University Hospitals
NHS Foundation Trust



Myeloproliferative Neoplasm (MPN) Clinical Trials Portfolio



NHS
National Institute for Health Research
Clinical Research Network

Recruiting Ph- MPN Trials

KRT-232-102 (Interventional) Polycythaemia Vera PI: Prof Adam Mead	A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera ***Eligibility Criteria:*** Age 18 or over, Diagnosis of PV, Phlebotomy dependent Part A: either Splenomegaly ≥ 450 cm^3 or absence of splenomegaly by CT/MRI; Part B: Splenomegaly by CT/MRI, Prior treatment with hydroxyurea (Part A and B) or interferon (Part A only) with resistance/intolerance to HU or IFN, ECOG performance status ≤ 2
KRT-232-101 (Interventional) Myelofibrosis PI: Prof Adam Mead	An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With PMF, PPV-MF, Or PET-MF Who Have Failed Ruxolitinib ***Eligibility Criteria:*** Age 18 or over, Diagnosis of PMF, PPV-MF, PET-MF, Palpable splenomegaly ≥ 5cm, DIPSS ≥ Intermediate-1, ECOG performance status ≤ 2 with adequate end organ function, Prior ruxolitinib treatment failure
MANIFEST (Interventional) Myelofibrosis PI: Prof Adam Mead	A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis) ***Eligibility Criteria:*** Age 18 and over, Phase 2: Diagnosis of MF, DIPSS ≥ Intermediate-1, ECOG performance status ≤ 2 with adequate end organ function, Palpable splenomegaly ≥ 5cm OR RBC transfusion dependent, At least 2 symptoms measurable, ANC ≥ 1 x 10^9/L, Platelet count ≥ 75 x 10^9/L
ACE-536 (Interventional) Myelofibrosis PI: Prof Adam Mead	A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with MPN-Associated Myelofibrosis and Anemia with or without Red Blood Cell-Transfusion Dependence ***Eligibility Criteria:*** Age 18 or over, Subject has MPN-associated myelofibrosis, Subject has anaemia and an ECOG performance score ≤2. Includes patients currently on ruxolitinib, but may also not be on the drug
TAMARIN (Interventional) All MPN PI: Prof Adam Mead	Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms ***Eligibility Criteria:*** PV,ET,MF, Stable disease on hydroxurea, interferon or ruxolutinib, No prior thrombosis, Age over 60, men aged between 50-59 may be considered, women must be post-menopausal
PHAZAR (Interventional) Accelerated or blast phase MPN PI: Prof Adam Mead	A Phase 1b Study to assess the safety and tolerability of oral Ruxolitinib in combination with Azacitidine in patients with Advanced Phase MPN, including MDS or AML arising from MPN ***Eligibility Criteria:*** Age 16 and over, Diagnosis of ET,PV or MF with > 10% bone marrow blasts (with or without dysplastic changes), ECOG performance status ≤ 3
INCYTE INCB 54828-203 (Interventional) Disorders with 8p11 PI: Prof Adam Mead	A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement ***Eligibility Criteria:*** Age 18 or over, Lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation and subjects who are not candidates for stem cell transplantation but have progressed
MEASURES (Non-interventional) All MPN PI: Prof Adam Mead	The MPN Experimental Assessment of Symptoms by Utilizing Repetitive Evaluation (MEASURES) Trial: Serial Assessment of Symptomatic Response to Non Experimental Medical Therapies and/or Phlebotomy in Patients with Myeloproliferative Neoplasms ***Eligibility Criteria:*** All Ph- MPN patients starting a new, therapeutic intervention.
INForMeD (Non-interventional) PI: Prof Adam Mead	An observational and biological research study to investigate the genetic and cellular basis of sporadic and familial myeloid disorders ***Eligibility Criteria:*** Age 2 or over, Patients under investigation for or diagnosed with a myeloid or related disorder, Patient willing to give consent to the study

Haematology Research contact details: Prof Adam Mead | Email: adam.mead@imm.ox.ac.uk | Tel: 01865 222324; Research Nurse Team | LP.Haematology.RN@oxnet.nhs.uk

Last updated: March 2019